Rxwire
In the news · 48h FDA 39 Eli Lilly 19 Roche 9 Merck & Co. (MSD) 8 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Novo Nordisk 3
Trials & R&D · first seen 19h ago, updated 19h ago

GSK slammed for ‘grossly misleading’ and ‘totally unacceptable’ behavior

1 outlet GSK

GSK showed a “totally unacceptable” lack of transparency in its interactions with the PMCPA, the U.K. self-regulatory body ruled.

Summary from Fierce Pharma - Marketing.

Coverage 1 article · 1 outlet

  1. Fierce Pharma - Marketing
    GSK slammed for ‘grossly misleading’ and ‘totally unacceptable’ behavior